SpringWorks Therapeutics Analyst Ratings
SpringWorks Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/20/2023 | 142.31% | HC Wainwright & Co. | $58 → $52 | Maintains | Buy |
11/09/2023 | 170.27% | HC Wainwright & Co. | $66 → $58 | Maintains | Buy |
08/24/2023 | 207.55% | HC Wainwright & Co. | → $66 | Reiterates | Buy → Buy |
08/07/2023 | 207.55% | HC Wainwright & Co. | $105 → $66 | Maintains | Buy |
07/20/2023 | 128.33% | Goldman Sachs | $43 → $49 | Maintains | Buy |
06/06/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | Buy → Buy |
05/05/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | → Buy |
04/28/2023 | 91.05% | Barclays | $55 → $41 | Maintains | Overweight |
04/20/2023 | 389.28% | HC Wainwright & Co. | → $105 | Reiterates | → Buy |
03/07/2023 | 165.61% | JP Morgan | $53 → $57 | Maintains | Overweight |
03/07/2023 | 389.28% | HC Wainwright & Co. | $99 → $105 | Maintains | Buy |
01/26/2023 | 109.69% | Goldman Sachs | $40 → $45 | Maintains | Buy |
12/01/2022 | 109.69% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
11/04/2022 | 361.32% | HC Wainwright & Co. | $103 → $99 | Maintains | Buy |
10/21/2022 | 105.03% | Goldman Sachs | $51 → $44 | Maintains | Buy |
09/12/2022 | 379.96% | HC Wainwright & Co. | $94 → $103 | Maintains | Buy |
08/09/2022 | 338.02% | HC Wainwright & Co. | $95 → $94 | Maintains | Buy |
06/06/2022 | 342.68% | HC Wainwright & Co. | $142 → $95 | Maintains | Buy |
05/27/2022 | 132.99% | Wedbush | $110 → $50 | Maintains | Outperform |
05/24/2022 | 282.11% | Goldman Sachs | $76 → $82 | Maintains | Buy |
09/08/2021 | 389.28% | JP Morgan | $97 → $105 | Maintains | Overweight |
08/05/2021 | 538.4% | HC Wainwright & Co. | $136 → $137 | Maintains | Buy |
07/21/2021 | 533.74% | HC Wainwright & Co. | $124 → $136 | Maintains | Buy |
03/22/2021 | 421.9% | Goldman Sachs | → $112 | Assumes | → Buy |
02/25/2021 | 477.82% | HC Wainwright & Co. | $101 → $124 | Maintains | Buy |
01/22/2021 | 328.7% | Barclays | $83 → $92 | Maintains | Overweight |
01/19/2021 | 370.64% | HC Wainwright & Co. | $87 → $101 | Maintains | Buy |
12/28/2020 | 305.41% | HC Wainwright & Co. | $73 → $87 | Reiterates | → Buy |
10/29/2020 | 240.17% | HC Wainwright & Co. | $58 → $73 | Maintains | Buy |
08/13/2020 | 132.99% | Wedbush | $48 → $50 | Maintains | Outperform |
05/13/2020 | 123.67% | Wedbush | $45 → $48 | Maintains | Outperform |
05/05/2020 | 123.67% | Barclays | → $48 | Initiates Coverage On | → Overweight |
04/14/2020 | 170.27% | HC Wainwright & Co. | $60 → $58 | Maintains | Buy |
03/19/2020 | 179.59% | HC Wainwright & Co. | $40 → $60 | Upgrades | Neutral → Buy |
03/04/2020 | 86.39% | HC Wainwright & Co. | → $40 | Downgrades | Buy → Neutral |
01/21/2020 | 86.39% | HC Wainwright & Co. | $34 → $40 | Maintains | Buy |
12/04/2019 | 53.77% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
10/08/2019 | 49.11% | JP Morgan | → $32 | Initiates Coverage On | → Overweight |
10/08/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
10/08/2019 | 53.77% | Wedbush | → $33 | Initiates Coverage On | → Outperform |
10/08/2019 | 72.41% | Goldman Sachs | → $37 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/20/2023 | 142.31% | HC Wainwright & Co. | 58 美元 → 52 美元 | 维护 | 买 |
11/09/2023 | 170.27% | HC Wainwright & Co. | 66 美元 → 58 美元 | 维护 | 买 |
08/24/2023 | 207.55% | HC Wainwright & Co. | → 66 美元 | 重申 | 购买 → 购买 |
08/07/2023 | 207.55% | HC Wainwright & Co. | 105 美元 → 66 美元 | 维护 | 买 |
07/20/2023 | 128.33% | 高盛 | 43 美元 → 49 美元 | 维护 | 买 |
06/06/2023 | 389.28% | HC Wainwright & Co. | → 105 美元 | 重申 | 购买 → 购买 |
05/05/2023 | 389.28% | HC Wainwright & Co. | → 105 美元 | 重申 | → 购买 |
04/28/2023 | 91.05% | 巴克莱 | 55 美元 → 41 美元 | 维护 | 超重 |
04/20/2023 | 389.28% | HC Wainwright & Co. | → 105 美元 | 重申 | → 购买 |
03/07/2023 | 165.61% | 摩根大通 | 53 美元 → 57 美元 | 维护 | 超重 |
03/07/2023 | 389.28% | HC Wainwright & Co. | 99 美元 → 105 美元 | 维护 | 买 |
01/26/2023 | 109.69% | 高盛 | 40 美元 → 45 美元 | 维护 | 买 |
2022 年 1 月 12 日 | 109.69% | B of A 类证券 | → 45 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 4 月 11 日 | 361.32% | HC Wainwright & Co. | 103 美元 → 99 美元 | 维护 | 买 |
10/21/2022 | 105.03% | 高盛 | 51 美元 → 44 美元 | 维护 | 买 |
09/12/2022 | 379.96% | HC Wainwright & Co. | 94 美元 → 103 美元 | 维护 | 买 |
08/09/2022 | 338.02% | HC Wainwright & Co. | 95 美元 → 94 美元 | 维护 | 买 |
2022 年 6 月 6 日 | 342.68% | HC Wainwright & Co. | 142 美元 → 95 美元 | 维护 | 买 |
05/27/2022 | 132.99% | Wedbush | 110 美元 → 50 美元 | 维护 | 跑赢大盘 |
2022 年 5 月 24 日 | 282.11% | 高盛 | 76 美元 → 82 美元 | 维护 | 买 |
09/08/2021 | 389.28% | 摩根大通 | 97 美元 → 105 美元 | 维护 | 超重 |
08/05/2021 | 538.4% | HC Wainwright & Co. | 136 美元 → 137 美元 | 维护 | 买 |
07/21/2021 | 533.74% | HC Wainwright & Co. | 124 美元 → 136 美元 | 维护 | 买 |
03/22/2021 | 421.9% | 高盛 | → 112 美元 | 假设 | → 购买 |
2021 年 2 月 25 日 | 477.82% | HC Wainwright & Co. | 101 美元 → 124 美元 | 维护 | 买 |
2021 年 1 月 22 日 | 328.7% | 巴克莱 | 83 美元 → 92 美元 | 维护 | 超重 |
01/19/2021 | 370.64% | HC Wainwright & Co. | 87 美元 → 101 美元 | 维护 | 买 |
12/28/2020 | 305.41% | HC Wainwright & Co. | 73 美元 → 87 美元 | 重申 | → 购买 |
10/29/2020 | 240.17% | HC Wainwright & Co. | 58 美元 → 73 美元 | 维护 | 买 |
08/13/2020 | 132.99% | Wedbush | 48 美元 → 50 美元 | 维护 | 跑赢大盘 |
05/13/2020 | 123.67% | Wedbush | 45 美元 → 48 美元 | 维护 | 跑赢大盘 |
05/05/2020 | 123.67% | 巴克莱 | → 48 美元 | 启动覆盖范围开启 | → 超重 |
2020 年 4 月 14 日 | 170.27% | HC Wainwright & Co. | 60 美元 → 58 美元 | 维护 | 买 |
2020 年 3 月 19 日 | 179.59% | HC Wainwright & Co. | 40 美元 → 60 美元 | 升级 | 中性 → 买入 |
03/04/2020 | 86.39% | HC Wainwright & Co. | → 40 美元 | 降级 | 买入 → 中性 |
2020 年 1 月 21 日 | 86.39% | HC Wainwright & Co. | 34 美元 → 40 美元 | 维护 | 买 |
2019 年 4 月 12 日 | 53.77% | HC Wainwright & Co. | → 33 美元 | 启动覆盖范围开启 | → 购买 |
2019 年 8 月 10 日 | 49.11% | 摩根大通 | → 32 美元 | 启动覆盖范围开启 | → 超重 |
2019 年 8 月 10 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
2019 年 8 月 10 日 | 53.77% | Wedbush | → 33 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
2019 年 8 月 10 日 | 72.41% | 高盛 | → 37 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for SpringWorks Therapeutics (SWTX)?
SpringWorks Therapeutics(SWTX)的目标价格是多少?
The latest price target for SpringWorks Therapeutics (NASDAQ: SWTX) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $52.00 expecting SWTX to rise to within 12 months (a possible 142.31% upside). 13 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月20日公布了SpringWorks Therapeutics(纳斯达克股票代码:SWTX)的最新目标股价。该分析公司将目标股价定为52.00美元,预计SWTX将在12个月内升至12个月内(可能上涨142.31%)。去年有13家分析公司公布了评级。
What is the most recent analyst rating for SpringWorks Therapeutics (SWTX)?
SpringWorks Therapeutics(SWTX)的最新分析师评级是多少?
The latest analyst rating for SpringWorks Therapeutics (NASDAQ: SWTX) was provided by HC Wainwright & Co., and SpringWorks Therapeutics maintained their buy rating.
SpringWorks Therapeutics(纳斯达克股票代码:SWTX)的最新分析师评级由HC Wainwright & Co. 提供,SpringWorks Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for SpringWorks Therapeutics (SWTX)?
SpringWorks Therapeutics(SWTX)的下一次分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SpringWorks Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SpringWorks Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与SpringWorks Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。SpringWorks Therapeutics的最新评级是在2023年11月20日公布的,因此你应该预计下一个评级将在2024年11月20日左右公布。
Is the Analyst Rating SpringWorks Therapeutics (SWTX) correct?
分析师对SpringWorks Therapeutics(SWTX)的评级正确吗?
While ratings are subjective and will change, the latest SpringWorks Therapeutics (SWTX) rating was a maintained with a price target of $58.00 to $52.00. The current price SpringWorks Therapeutics (SWTX) is trading at is $21.46, which is out of the analyst's predicted range.
尽管评级是主观的,而且会发生变化,但SpringWorks Therapeutics(SWTX)的最新评级维持不变,目标股价为58.00美元至52.00美元。SpringWorks Therapeutics(SWTX)目前的交易价格为21.46美元,超出了分析师的预期区间。